Browse > Article
http://dx.doi.org/10.12925/jkocs.2009.26.3.8

Synthesis of New Benzaminoquinoline Derivatives with Antiproliferative Activity against Melanoma Cell Line  

Yoo, Kyung-Ho (Biomaterials Research Center, Korea Institute of Science and Technology)
Nam, Bong-Soo (Biomaterials Research Center, Korea Institute of Science and Technology)
Publication Information
Journal of the Korean Applied Science and Technology / v.26, no.3, 2009 , pp. 297-305 More about this Journal
Abstract
Melanoma is the most serious type of skin cancer as a malignant tumor of melanocytes. In this work, the syntheses of a novel series of benzaminoquinoline derivatives 1a-c and their antiproliferative activities against A375 human melanoma cell line were described. All the compounds ($IC_{50}=0.78-1.02{\mu}M$) showed superior antiproliferative activities to Sorafenib ($IC_{50}=5.58{\mu}M$) as a reference compound. These results suggested that benzaminoquinoline derivatives have potentials as a therapeutic agent for the treatment for melanoma.
Keywords
benzaminoquinolines; syntheses; antiproliferative activity; melanoma cell line;
Citations & Related Records
연도 인용수 순위
  • Reference
1 B. J. Druker and N. B. Lydon, Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia, J Clin Invest., 105, 3 (2000)
2 R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, ]. Rigas, G. M. Clark, P. Santabarbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non - Small-Cell Lung Cancer, J Clin Oneal., 22, 3238 (2004)   DOI   ScienceOn
3 C. Garbe, A. Hauschild, M. Volkenandt, D. Schadendorf, W. Stolz, U. Reinhold, R. D. Kortmann, C. Kettelhack, B. Frerich, U. Keilholz, R. Dummer, G. Sebastian, W. Tilgen, G. Schuler, A. Mackensen, and R. Kaufmann, Evidence and Interdisciplinary Consense-based C'xerman Guidelines: Diagnosis and Surveillance of Melanoma, Melanoma Res., 17, 393 (2007)   DOI   ScienceOn
4 A. C. Buzaid and C. M. Anderson, The Changing Prognosis of Melanoma, Curro Oneal. Rep., 2, 322 (2000)   DOI   ScienceOn
5 S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, Preclinical Overview of Sorafenib, a Multikinase Inhibitor that Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling, Mol. Cancer Ther., 7, 3129 (2008)   DOI   ScienceOn
6 C. M. Anderson, A. C. Buzaid, and S. S. Legha, Systemic Treatments for Advanced Cutaneous Melanoma, Oncology, 9, 1149 (1995)
7 D. H. Lawson, Choices in Adjuvant Therapy of Melanoma, Cancer Control, 12, 236 (2005)   PUBMED
8 L. Serrone, M. Zeuli, F. M. Sega, and F. Cognetti, Dacarbazine-based Chemotherapy for Metastatic Melanoma: Thirty-year Experience Overview, J. Exp. Clin. Cancer Res., 19, 21 (2000)   PUBMED
9 S. A. Rosenburg, M. T. Lotze, J. c. Yang, P. M. Aebersold, W. M. Linehan, C. A. Seipp, and D. E. White, Experience with the Use of High Dose Interleukin-2 in the Treatment of 652 Cancer Patients, Ann. Surg., 210, 474 (1989)   DOI   ScienceOn
10 L. V. Dubey and I. V. Dubey, Side Reactions of Onium Coupling Reagents BOP and HBTU in the Synthesis of Silica Polymer Supports, Ukr. Bioorg. Acta, 1, 13 (2005)
11 J. A. Carlson, J. S. Ross, A. Slominski, G. Linette, J. Mysliborski, J. Hill, and M. Mihm, Jr., Molecular Diagnostics In Melanoma, J Am Arod Dermatol., 52, 743 (2005)   DOI   ScienceOn
12 W. S. Fletcher, D. S. Daniels, V. K. Sondak, B. Dana, R. Townsend, H. E. Hynes, L. F. Hutchins, and ]. R. Pancoast, Evaluation of Cisplatin and DTIC in Inoperable Stage III and IV Melanoma, Am J. Clin. Oncol., 16, 359 (1993)   DOI   ScienceOn
13 M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, and N. Thatcher, Randomized Phase III Study of Temozolomide versus Dacarbazine in the Treatment of Patients with Advanced Metastatic Malignant Melanoma, J Clin Oneal., 18, 158 (2008)
14 M. B. Atkins, M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg, High-dose Recombinant Interleukin 2 Therapy for Patients with Metastatic Melanoma: Analysis of 270 Patients Treated between 1985 and 1993, J. Clin. Oncol., 17, 2105 (1999)   DOI   PUBMED
15 A. L. Ruchelman, J. E. Kenigan, T. - K. Li, N. Zhou, A. Liu, L. F. Liu, E. J. LaVoie, Nitro and Amino Substitution within the A-ring of 5H-S,9- dimethoxy-5- (2-N ,N -dimethylaminoethyl) dibenzo[c,h] [l,6]naphthyridin -6-ones: Influence on Topoisomerase I-Targeting Activity and Cytotoxicity, Bioorg. Med Chem, 12, 3731 (2004)   DOI   ScienceOn
16 A. Y. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. C. Pavlick, R. DeConti, E. M. Hersh, P. Hersey, J. M. Kirkwood, and F. G. Haluska, Bd-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group, J Clin Oneal., 24, 4738 (2006)   DOI   ScienceOn
17 S. A. Laufer, D. M. Domeyer, T. R. F. Scior, W. Albrecht, D. R. ]. Hauser, Synthesis and Biological Testing of Purine Derivatives as Potential A TP-competitive Kinase Inhibitors, J. Med Chem, 48, 710 (2005)   DOI   ScienceOn
18 D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZDI839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin Oneal., 29 (Supplement 4), 37 (2002)